Abstract Introduction The REGAL (RSV Evidence–A Geographical Archive of the Literature)
series has provided a comprehensive review of the published evidence in the field of …

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract
infections in infants and young children, accounting for more than 100,000 hospitalizations …

Respiratory syncytial virus (RSV) is a major cause of hospitalizations due to pneumonia and
bronchiolitis. Substantial morbidity and socioeconomic burden are associated with RSV …

Morbidity due to respiratory syncytial virus (RSV) disease is still high in infants and children
worldwide during the first two to five years of life. Certain categories of high-risk infants with …

Respiratory Syncytial Virus (RSV) is a common virus that infects children and adults;
however, children younger than two years of age tend to develop more serious respiratory …

The Food and Drug Administration recently approved the use of palivizumab (palē-vizhū-
mäb), an intramuscularly administered monoclonal antibody preparation …

Background: Prophylactic therapy with palivizumab, a humanized monoclonal antibody, has
been shown to reduce the number of respiratory syncytial virus (RSV)—related …

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early
childhood and palivizumab is the only licensed intervention for prevention. Palivizumab …

Respiratory syncytial virus (RSV) is a major viral pathogen whichcauses serious respiratory
illness in infants and children worldwide. Palivizumab (Synagis) is an anti‐RSV monoclonal …

In respiratory syncytial virus (RSV) disease the balance between the innate and adaptive
immune responses determines the expression of the pathological phenotype favoring the …